... potency were developed as chemo- and radio-sensitizers and first entered clinical trial in cancer patients in 2003. However, it was the revelation in 2005 that they were synthetically lethal in cells with DNA repair defects, found almost exclusively in some tumours, that led to a major interest...

...@uni-muenster.de ). 9 6 2006 © 2006 The Biochemical Society 2006 clinical trial neuroprotective drug neuroprotection stroke thrombolysis trial development Despite several advantages in stroke care and therapy, only a small number of acute stroke patients (3%) receive...